Top

Cancer Immunology, Immunotherapy

Published in:

Open Access 01-07-2024 | Cutaneous Squamous Cell Carcinoma | Brief Report

Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy

Authors: Barbara Bailly-Caillé, Romain Levard, Diane Kottler, Anne Dompmartin, Jean-Matthieu L’Orphelin

Published in: Cancer Immunology, Immunotherapy | Issue 7/2024

Abstract

Background

In a princeps study we conducted in patients with advanced cutaneous squamous cell carcinoma treated with concomitant anti-Programmed cell death protein 1 (PD-1) and radiotherapy, we demonstrated a clinico radiological response to cemiplimab that appeared to persist over time, 1 year after treatment discontinuation.

Method

We conducted a single-center descriptive study at Caen Hospital from September 1, 2021 to September 2023, in 14 patients with advanced carcinoma treated with cemiplimab until September 1, 2021. The aim of this update is to examine clinical and radiological follow-up 2 years after discontinuation of cemiplimab.

Results

Of the 12 patients with a partial or complete response, we report 8 (66.7%) persistent responses 2 years after stopping cemiplimab, with only 2 patients progressing to distant disease, one lost to follow-up, and one death a priori unrelated to the disease.

Conclusion

Our study confirms a long-term and persistent effect despite discontinuation of cemiplimab at least up to 2 years later.

Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Van Akkooi A, Bataille V et al (2023) European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: part 2. Treatment–Update 2023. Eur J Cancer 193:113252. https://doi.org/10.1016/j.ejca.2023.113252. Epub 2023 Jul 28. PMID: 37708630

Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R et al (2020) Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer 138:125–132. https://doi.org/10.1016/j.ejca.2020.07.029. (Epub 2020 Aug 31 PMID: 32882466)CrossRefPubMed

Hober C, Fredeau L, Pham-Ledard A, Boubaya M, Herms F, Celerier P et al (2021) Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: real-life experience from the French CAREPI Study Group. Cancers (Basel) 13(14):3547. https://doi.org/10.3390/cancers13143547.PMID:34298764;PMCID:PMC8305372CrossRefPubMed

Baggi A, Quaglino P, Rubatto M, Depenni R, Guida M, Ascierto PA, et al (2022) Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Eur J Cancer 157:250–258. https://doi.org/10.1016/j.ejca.2021.08.018. Epub 2021 Sep 15. Erratum in: Eur J Cancer 166:309–310. PMID: 34536948

Bailly-Caillé B, Kottler D, Morello R, Lecornu M, Kao W, Meyer E et al (2023) Real-life study of the benefit of concomitant radiotherapy with cemiplimab in advanced cutaneous squamous cell carcinoma (cSCC): a retrospective cohort study. Cancers (Basel) 15(2):495. https://doi.org/10.3390/cancers15020495.PMID:36672444;PMCID:PMC9856754CrossRefPubMed

Presley CJ, Gomes F, Burd CE, Kanesvaran R, Wong ML (2021) Immunotherapy in older adults with cancer. J Clin Oncol. 39(19):2115–2127. https://doi.org/10.1200/JCO.21.00138. Epub 2021 May 27. PMID: 34043444; PMCID: PMC8260908

Migden MR, Schmults C, Khushanlani N, Guminski A, Chang AL, Lewis K et al (2022) 814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3. Ann Oncol 33:S918–S919. https://doi.org/10.1016/j.annonc.2022.07.940.

Gerard E, Lebbe C, Lanoy E, Quereux G, Bernard P, Viguier MA et al.(2023) 1140P Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA. Ann Oncol 34:S683. https://doi.org/10.1016/j.annonc.2023.09.2274.

Yushak ML, Lawson DH, Goings M, Mckellar M, Maynard N, Woodruff KS et al. (2019) Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma: an updated analysis. J Clin Oncol. 37(15_suppl):e21015‑e21015. https://doi.org/10.1200/JCO.2019.37.15_suppl.e21015.

10.

Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ et al. (2022) Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 387(17):1557–1568. https://doi.org/10.1056/NEJMoa2209813. Epub 2022 Sep 12. PMID: 36094839; PMCID: PMC9844515.

11.

Tachiki LML, Hippe DS, Williams Silva K, Hall ET, McCamy W, Fritzsche D et al. (2023) Bhatia S. Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma. Cancer Immunol Immunother 72(11):3839–3850. https://doi.org/10.1007/s00262-023-03539-8. Epub 2023 Sep 21. Erratum in: Cancer Immunol Immunother 72(12):4471. PMID: 37733060; PMCID: PMC10576731

12.

Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, van Akkooi A, Bataille V et al. (2023) European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: diagnostics and prevention-Update 2023. Eur J Cancer 193:113251. https://doi.org/10.1016/j.ejca.2023.113251. Epub 2023 Jul 28. PMID: 37717283

13.

Ruiz ES, Kus KJB, Smile TD, Murad F, Zhou G, Ilori EO et al (2022) Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: a dual-center retrospective study. J Am Acad Dermatol 87(1):87–94. https://doi.org/10.1016/j.jaad.2022.03.044. (Epub 2022 Mar 29 PMID: 35364211)CrossRefPubMed

14.

Kim Y, Lehrer EJ, Wirth PJ, Khesroh EA, Brewer JD, Billingsley EM et al (2022Jun) Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: A systematic review and meta-analysis. J Am Acad Dermatol 86(6):1246–1257. https://doi.org/10.1016/j.jaad.2021.11.059. (Epub 2021 Dec 7 PMID: 34890701)CrossRefPubMed

Title: Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy
Authors: Barbara Bailly-Caillé
Romain Levard
Diane Kottler
Anne Dompmartin
Jean-Matthieu L’Orphelin
Publication date: 01-07-2024
Publisher: Springer Berlin Heidelberg
Keywords: Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Radiotherapy
Published in: Cancer Immunology, Immunotherapy / Issue 7/2024
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-024-03700-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2024

The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study

Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer

Epigenetic silencing of LDHB promotes hepatocellular carcinoma by remodeling the tumor microenvironment

Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study

Effect of radiochemotherapy on peripheral immune response in glioblastoma

Integrative analysis of single-cell and bulk RNA sequencing unveils a machine learning-based pan-cancer major histocompatibility complex-related signature for predicting immunotherapy efficacy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer